The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase IIa study of marrow infiltrating lymphocytes (MILs), an adoptive T cell therapy, alone or in combination with nivolumab in non-small cell lung cancer (NSCLC).
 
Martin Edelman
Stock and Other Ownership Interests - Biomarker Strategies; Neumedicines
Consulting or Advisory Role - ARMO BioSciences; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Syndax; WindMIL
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Nektar (Inst); United Therapeutics (Inst); Windmil (Inst)
Patents, Royalties, Other Intellectual Property - Patent application for radiopharmaceutical to treat small cell lung cancer. (Inst)
Travel, Accommodations, Expenses - ARMO BioSciences; BerGenBio; BerGenBio; Bristol-Myers Squibb
Other Relationship - AstraZeneca/MedImmune; Boehringer Ingelheim; Lilly; Takeda
 
Aaron Elliott Lisberg
Employment - Boston Scientific (I)
Stock and Other Ownership Interests - Boston Scientific (I)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Jazz Pharmaceuticals; Leica Biosystems; Novocure; Pfizer
Research Funding - AstraZeneca; Calithera Biosciences; Daiichi Sankyo; Dracen
 
Marianna Koczywas
Speakers' Bureau - AstraZeneca; Celgene
 
Ben C. Creelan
Consulting or Advisory Role - Abbvie; ARMO BioSciences; AstraZeneca/MedImmune; BerGenBio; Boehringer Ingelheim; E.R. Squibb Sons, LLC; Gilead Sciences; GlaxoSmithKline; KSQ Therapeutics
Speakers' Bureau - ARIAD; AstraZeneca/MedImmune; Foundation Medicine; Genentech/Roche; Takeda
Research Funding - Biodesix (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); NeoGenomics Laboratories (Inst); Prometheus (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Amanda Seiz
Employment - WindMIL
Stock and Other Ownership Interests - Precision for Medicine
Travel, Accommodations, Expenses - WindMIL
 
Eric Lutz
Employment - WindMIL
Stock and Other Ownership Interests - WindMIL
Patents, Royalties, Other Intellectual Property - WindMIL
Travel, Accommodations, Expenses - WindMIL
 
Lakshmi Rudraraju
Employment - WindMIL
Stock and Other Ownership Interests - WindMIL
 
Elizabeth DeOliveria
Employment - WindMIL
Stock and Other Ownership Interests - WindMIL
 
Monil Shah
Employment - WindMIL
Leadership - WindMIL
Stock and Other Ownership Interests - WindMIL
 
Kim Noonan
Employment - WindMIL
Leadership - WindMIL
Stock and Other Ownership Interests - WindMIL; Y-Trap Inc.
Consulting or Advisory Role - Y-Trap Inc.
Patents, Royalties, Other Intellectual Property - WindMIL
Other Relationship - WindMIL; Y-Trap Inc.
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Achilles Therapeutics (Inst); Association of Community Cancer Centers (ACCC) (Inst); Astellas Pharma (I); AstraZeneca (Inst); Atreca (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Shattuck Labs (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); University of Michigan (Inst); WindMIL (Inst)
Travel, Accommodations, Expenses - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; EMD Serono; Exelixis; Genentech; Incyte; Janssen Oncology; Lilly; Merck; Novartis; Pfizer; Sanofi; Sysmex; Vapotherm